1 / 52

FDA Review of Clinical Data Laronidase for the treatment of Mucopolysaccharidosis I

FDA Review of Clinical Data Laronidase for the treatment of Mucopolysaccharidosis I BioMarin Pharmaceuticals, Inc. FDA/Center for Biologics Evaluation and Research. Introduction. BioMarin proposes the use of laronidase for the treatment of patients with MPS I

ondrea
Download Presentation

FDA Review of Clinical Data Laronidase for the treatment of Mucopolysaccharidosis I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FDA Review of Clinical Data Laronidase for the treatment of Mucopolysaccharidosis I BioMarin Pharmaceuticals, Inc. FDA/Center for Biologics Evaluation and Research

  2. Introduction • BioMarin proposes the use of laronidase for the treatment of patients with MPS I • Proposed dose: 0.58 mg / kg(100 U / kg) IV administered once weekly

  3. MPS I • MPS I: lysosomal storage disease due to a genetic deficiency of a-L-iduronidase (IDU) • Progressive accumulation of glycosaminoglycans or GAG (Heparan sulfate and Dermatan sulfate) • MPS I affects multiple tissues and organs, leading to death during childhood in the most severe form • Morbidity and mortality usually from airway / pulmonary or cardiomyopathy / valvular disorders • 3 broad clinical categories (MPS I H, H-S, S) by severity, are arbitrary definitions in a continuum spectrum

  4. MPS I: Clinical Background • Diagnosis: IDU assay: serum, WBC’s, skin fibroblasts • Treatment: Supportive care only, for complications • Allogeneic BMT restricted to most severe MPS I Hurler: can be effective but usually limited to patients younger than 2 years. • Significant morbidity and mortality with this treatment, and without benefits to treat/ prevent neurologic decline

  5. Clinical Studies In all studies same Laronidase dose used

  6. BIO7500 • Non-controlled, open label • Initial study period: 26 weeks, extended and ongoing • 10 subjects • Male / female, age: older than 5 years • Enzymatic deficiency • Hepatosplenomegaly, ­GAG • Dose: 0.58 mg / kg IV over 3-4 hours, weekly

  7. BIO 7500 Notable evaluations • Liver / spleen volume by MRI • Urinary GAG per mg creatinine • Shoulder, knee, elbow ROM • Cardiac assessments • Airway assessments (Sleep study, MRI of airway index) • CNS: brain, cervical cord MRI

  8. BIO7500 Results • Liver volume: all reduced ≥ 20% by 1 year • Urinary GAG: all reduced ≥ 50% by week 6 • Most subjects had improvements in: • joint ROM (particularly shoulder flexion) • NYHA scores • Sleep apnea • Echo, visual acuity, CNS abnormalities, bone evaluations showed no change • Non-controlled, open label nature of this study precludes any conclusions about clinical efficacy

  9. BIO7500 Safety Results • Safety: • 8 / 10 subjects: SAE’s (allergic reactions, pneumonia, cervical cord compression, hydrocephalus) • 2 of these: death • Subject 008 (age 7) died after wk 103: • Respiratory distress and arrest • Viral lymphocytic myocarditis, bronchiolitis • High anti-laronidase IgG throughout study • Complement activation weeks 6-12 • Subject 002 (age 13) died after wk 137: • After surgical procedure

  10. BIO7500 Safety Results (Cont.) • Immunogenicity • 10 / 10 (+) by ELISA, 4 / 10 (+) by Western Blot (more specific). • Titers generally peak at 8-20 weeks and decline over time.

  11. BIO7500 Conclusion • Demonstration of bioactivity in liver GAG accumulation and urinary GAG excretion • No apparent correlation between IgG titers and reduction in liver / spleen size or urinary GAG • Open label, non-controlled study design does not allow conclusion of efficacy

  12. Study 003 • Randomized, Double-blind, Placebo-controlled, Multinational study • Duration: 26 weeks of treatment • Eligibility: • Male / female, age older than 5 years • IDU Enzyme activity < 10 % LLN • Signs and symptoms of MPS I • Baseline predicted FVC ≤ 80% • Dose: 0.58 mg / kg IV weekly

  13. Study 003 Notable evaluations • Pulmonary function tests • 6 minute walk distance (6MWD) • Sleep study • Liver volume • Urinary GAG • Joint ROM • EKG / echo

  14. Study 003 Endpoints • Primary: • Mean change from baseline to week 26 in % FVC based on current height • Mean absolute change from baseline to week 26 in 6MWD • Analysis method: Wilcoxon Rank Sum (ITT subjects) • Statistically significant only if both p < 0.05

  15. Study 003 Endpoints • Secondary: • AHI • Liver volume • Shoulder flexion • Disability index from CHAQ / HAQ • Multiple tertiary endpoints

  16. Study 003 Results • 45 subjects were randomized • 22 laronidase and 23 placebo • 5 centers

  17. Study 003 Results Demographic & Baseline characteristics

  18. Study 003 ResultsBaseline Characteristics (Cont.) • Both groups similar regarding: • Time from onset of symptoms • Time from diagnosis • Enzyme activity (± 1.5 %) • Weight and height • Baseline % FVC and 6MWD were lower in laronidase group, compared to placebo

  19. Study 003 Results % FVC

  20. Study 003: % FVC by study visit

  21. Study 003 FVC • FVC in absolute volume change from baseline to week 26: • Laronidase: 0.11 ± 0.14 L • Placebo: - 0.02 ± 0.13 L • p < 0.01

  22. Study 003: % FVC by gender and study visit(baseline height)

  23. 7-12 13-18 19-65 Laronidase 0 Placebo 0 Laronidase 26 Placebo 26 Study 003 Results % FVC by age category

  24. Study 003 Impairment % FVC at baseline Least Most

  25. Study 003 Results% FVC by impairment versus gender • Distribution of subjects: • Most laronidase males in the 2 most impaired %FVC categories at baseline • Most laronidase females in the 2 least impaired %FVC categories at baseline • Therefore, the effect of gender cannot be distinguished from the effect of impairment at baseline for laronidase subjects

  26. Study 003 6 Minute Walk Distance D wk 0 - 26 Placebo: -18 meters Dwk 0- 26 Laronidase: 20 meters p=0.07

  27. Study 003 6 MWD

  28. Study 003: 6 MWD by gender & study visit

  29. Study 003 6 MWD by impairment at baseline Quartiles of baseline distance walked (m)

  30. 7-12 13-18 19-65 Laronidase 0 Placebo 0 Laronidase 26 Placebo 26 Study 003 6 MWD by age category

  31. Study 003 2nd EP: Apnea Hypopnea IndexChange in AHI from baseline to week 26

  32. Study 003 Secondary endpoints (Cont.) • Liver volume: • Laronidase: -19 % (n=22) • Placebo: +1 % (n=22) • P = 0.001 • Similar to Phase 1 data • Disability Index: no difference between groups • Shoulder flexion: no difference between groups

  33. Study 003 Tertiary Endpoints • Urinary GAG: • Substantial decrease as early as week 4 among laronidase subjects • Change from baseline to week 26: • Laronidase: - 108 mcg / g creatinine • Placebo: + 67 mcg / g creatinine • P < 0.001 • Other endpoints: no difference between groups

  34. Study 003 Pharmacokinetic studies • 12 laronidase subjects assessed at infusion 1, 12 and 26 • Cmax :slight ­ (0.2 to 0.3 U/mL) over study period • Volume of distribution (Vz): ¯ wk 1 - 12 (0.6 to 0.3 L/Kg) • Decrease in Vz may be affected by antibody formation • Inverse correlation between antibody titers and Vz • Unknown if distribution of antibody bound-laronidase is different than unbound enzyme • Unknown if antibody formation affects differential lysosomal uptake among organs and tissues

  35. Study 003 Safety • AE’s mostly related to infusions of the assigned study agent • Prevalence in treatment groups • 11/ 23 placebo had 82 IAR’s • 7 / 22 laronidase had 66 IAR’s • Most common: headache, flushing and rash • Severe AE’s were most likely related to MPS I • SAE’s: • Hospital admission for abdominal pain (constipation) • Cardiac valvular disease worse requiring surgery. Complicated by cardiac arrest, sepsis, renal failure • Partial obstruction of ventricular shunt.

  36. Study 003 Safety (Cont.) • Labs: positive anti-laronidase IgG by RIP: • 20 laronidase subjects from weeks 4 or 8 to week 26 • 1 placebo subject (one visit only) • (-) IgE and complement activation in 3 IAR’s

  37. Study 003 Conclusions • Effect of laronidase on primary endpoints: • % FVC • Small effect size (mean increase 110 mL or 5.3 % predicted) (p=0.02) • Time course: Abrupt ­ wk 20 – 26 in laronidase, abrupt ¯ wk 0 – 4 in placebo, unexplained • Non uniform across subsets:­ effect in female and milder pulmonary restriction at baseline • 6 Minute Walk Distance • 38 m absolute mean difference, (p=0.07) • Non uniform across subsets: ­ effect in younger, female, with larger distance walked at baseline

  38. Study 003 Conclusions (Cont.) • AHI some suggestion of benefit in more severely affected subjects only • Pharmacodynamic effects on liver volume and urinary GAG in all subjects • Frequent infusion reactions in both treatment groups, generally mild to moderate • Anti-laronidase IgG formation nearly universal • Pharmacokinetic data suggestive of changes over time. Unclear long term consequences

  39. Study 006 • Open label, non-controlled extension study to 003 • All 45 subjects enrolled • Ongoing study (data from first 24 weeks presented) • Laronidase administered at 0.58 mg / kg (100 U / kg) IV weekly • Infusions performed at the 5 original sites or at 13 regional sub-sites. • Most evaluations at study entry (week 26 of Study 003) and every 12 weeks

  40. Study 006 % FVC by study visit Controlled Noncontrolled

  41. Study 006ChangesFVC by GenderStudy 003 or 006

  42. Study 006 Changes FVC by Age in Study 003 or 006

  43. Study 006 % FVC changes • Changes in absolute lung volumes were very small and similar for both groups • Unlike Study 003 data showing greater effect in less impaired laronidase subjects, no pattern can be seen during 24 weeks of Study 006 between groups across the quartiles of baseline % FVC impairment. This finding is expected due to absence of overall treatment effect.

  44. Study 006 6MWD Noncontrolled Controlled

  45. Study 006 Results6MWD in subset analyses • Gender: similar changein males / females of both groups • Age category: similar changein the 3 age categories of both groups • Severity at baseline: similar change in all quartiles of severity at baseline of both groups

  46. 2nd EP: AHI Changes in Studies 003 and 006

  47. Study 006: Other Endpoints • Liver volume decreased by 12.6 % in the placebo/laronidase group • Compare to 19 % decrease in the laronidase group in Study 003 • Both groups had a mean 6 degrees improvement in shoulder flexion during Study 006 • Disability Index was unchanged in both treatment groups during Study 006 • Urinary GAG ¯ a mean 69 % in the placebo/laronidase group

  48. Study 006 Safety • AE’s reported similar to those in Study 003 • One death (placebo/laronidase) of complication of URI/bronchitis • One notable SAE: life-threatening infusion reaction (anaphylactic) requiring emergency tracheostomy

  49. Study 006 Safety • 40 / 45 subjects in Study 006 developed anti-laronidase IgG by RIP assay • 21/23 placebo/laronidase became (+) during Study 006 • 20/22 laronidase/laronidase were (+) at entry, and another subject became (+) during Study 006; 2 (+) subjects became (-) after being (+) during Study 003. • No correlation with AE’s or IAR’s

  50. Study 006 Conclusions • % FVC: No changes in either group during study • 6MWD: 20 meters mean increment for both groups • No clear trend in subsets (age, gender, impairment) • Liver volume and urinary GAG were substantially reduced • Data in other secondary and tertiary endpoints were inconclusive

More Related